NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Clinical Trials
1
Data completeness
3/8 — Basic
LIDOCAINE HYDROCHLORIDE (lidocaine hydrochloride) by Medica Corp is 12. Approved for pain, prostate cancer.
Drug data last refreshed 1w ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lidocaine hydrochloride is a local anesthetic that stabilizes neuronal membranes by inhibiting ionic fluxes required for impulse initiation and conduction. It is administered via injection for pain management and has an investigational indication in prostate cancer. The drug is currently in pre-launch phase under NDA review by Medica Corp.
Pre-Launch
Pre-launch stage indicates small commercial team; significant growth opportunity if prostate cancer indication gains traction, but faces entrenched competition from established therapies.
Mechanism of Action
12.1 Mechanism of Action Lidocaine hydrochloride stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. 12.2 Pharmacodynamics Excessive blood levels may cause changes in cardiac output, total…
Worked on LIDOCAINE HYDROCHLORIDE at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.